Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
698 A phase 2 study of durvalumab combined with chemotherapy and stereotactic body radiotherapy (SBRT) in patients with oligometastatic non-small cell lung cancer (NSCLC) (SABRCURE trial)
Compose a Response to This Article
Other responses
No responses have been published for this article.